Coronavirus Series – Part 1:
Antiviral Measures Targeting Coronavirus Entry
Thursday, July 30, 2020, 1:00 pm – 2:30 pm ET
COVID-19 first began in late 2019 and as of July 2020 approximately 12 million people have been infected with a mortality rate of over 4% globally. The SARS-CoV-2 virus is differentiated from the many common coronavirus variants, including those
associated with the common cold, by its cross-species infectivity, rapid spread, and lethality. Rapid advances in the identification of this new coronavirus, and its putative host susceptibility factor, angiotensin converting enzyme 2
(ACE2) as the SARS-CoV-2 cell surface receptor, have led to the proliferation of clinical drug repurposing and preclinical rational drug design efforts to combat this devastating pandemic.
Dr. Thomas Gallagher is a leading expert on the virology of coronaviruses. His talk will provide an overview of the virology of coronaviruses, the current understanding of SARS-CoV-2 viral entry and provide critical insights regarding various interventional
strategies to limit infectivity. Given the ongoing societal and economic impact of COVID-19 pandemic world-wide, this seminar will be of great interest to all ASPET members.
Michael F. Jarvis, PhD, FBPhS - AbbVie
Qing Ma, PharmD, PhD – University at Buffalo
Thomas Gallagher, PhD
Loyola University Chicago, Department of Microbiology and Immunology